Stock listing

Frankfurt:PI6 Palvella Therapeutics, Inc. Aktie

German listing (Frankfurt) of Palvella Therapeutics, Inc. · home listing NASDAQ:PVLA

Follow Palvella Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:PI6

€112.00 EUR +1.00 (+0.9%)

Close on Oct 27, 2026

Day range
€112.00 – €112.00 EUROct 27, 2026
Market cap
€1.61B EURAt the close on Oct 27, 2026 · price × 14.34M shares outstanding
Palvella Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PVLA · Home$146.33 USD+0.18 (+0.1%)303,458$145.04$150.00$141.98$146.15Close on Nov 2, 2026
Frankfurt:PI6€112.00 EUR+1.00 (+0.9%)—€112.00€112.00€112.00€111.00Close on Oct 27, 2026
Ticker
Frankfurt:PI6
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Palvella Therapeutics (NASDAQ:PVLA) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 8:30 AM ET

    Register

Replays

  • Palvella Therapeutics (NASDAQ:PVLA) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 8:30 AM ET

    Watch Transcript

  • Palvella Therapeutics (NASDAQ:PVLA) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:30 AM ET

    Watch Transcript

  • Palvella Therapeutics (NASDAQ:PVLA) Q4 2025 Earnings Call

    Tue, Mar 31, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference

Nov 3, 2026

Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026

Oct 29, 2026

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

Oct 28, 2026

Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference

Oct 15, 2026

Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Oct 13, 2026

Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026

Oct 12, 2026

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Sep 28, 2026

Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Sep 2, 2026

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Aug 5, 2026

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 4, 2026

All Palvella Therapeutics, Inc. news

Decks

Palvella Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
48 in the last 12 months · 122 in all · newest Nov 3, 2026 · oldest 2021
Calls
7 calls with a replay · 7 with a transcript · latest Aug 4, 2026
Decks
23 decks · latest Aug 4, 2026

Where Palvella Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PVLA · Home listingNASDAQUnited StatesUSD
gettex:PI6gettexGermanyEUR
BOATS:PVLABOATSUnited StatesUSD
Frankfurt:PI6 · This pageFrankfurtGermanyEUR
Munich:PI6MunichGermanyEUR
Tradegate:PI6TradegateGermanyEUR
LS Exchange:A40RA6LS ExchangeGermanyEUR

Log in to ask 6ix AI your own questions about Palvella Therapeutics, Inc.